NovAccess Global Inc. (XSNX)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.19 Million USD | 70.6% |
| 2022 | 1.28 Million USD | 319.3% |
| 2021 | 307.53 Thousand USD | 26.56% |
| 2020 | 242.99 Thousand USD | 9.8% |
| 2019 | 221.29 Thousand USD | -8.22% |
| 2018 | 241.1 Thousand USD | -7.74% |
| 2017 | 261.32 Thousand USD | -11.08% |
| 2016 | 293.88 Thousand USD | 29.23% |
| 2015 | 227.41 Thousand USD | -9.43% |
| 2014 | 251.09 Thousand USD | 234.95% |
| 2013 | 74.96 Thousand USD | -81.87% |
| 2012 | 413.46 Thousand USD | -9.51% |
| 2011 | 456.92 Thousand USD | 0.0% |
| 2010 | 456.92 Thousand USD | 0.0% |
| 2009 | 456.92 Thousand USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | -100.0% |
| 2005 | 850 Thousand USD | 69287.76% |
| 2004 | 1225.00 USD | 0.0% |
| 2003 | - USD | -100.0% |
| 2002 | 195.72 Thousand USD | 1.75% |
| 2001 | 192.35 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 2.18 Million USD | -0.57% |
| 2024 Q3 | 34 Thousand USD | -3.24% |
| 2024 Q2 | 2.16 Million USD | -1.04% |
| 2023 Q3 | 1.9 Million USD | 7.26% |
| 2023 Q2 | 1.77 Million USD | 15.54% |
| 2023 FY | 2.19 Million USD | 70.6% |
| 2023 Q4 | 2.19 Million USD | 15.31% |
| 2023 Q1 | 1.53 Million USD | 19.38% |
| 2022 Q2 | 744.24 Thousand USD | 21.49% |
| 2022 Q3 | 739.76 Thousand USD | -0.6% |
| 2022 Q4 | 1.28 Million USD | 74.31% |
| 2022 FY | 1.28 Million USD | 319.3% |
| 2022 Q1 | 612.58 Thousand USD | 99.19% |
| 2021 Q1 | 220.13 Thousand USD | -9.41% |
| 2021 Q2 | 246.2 Thousand USD | 11.85% |
| 2021 Q3 | 199.69 Thousand USD | -18.89% |
| 2021 Q4 | 307.53 Thousand USD | 54.01% |
| 2021 FY | 307.53 Thousand USD | 26.56% |
| 2020 Q1 | 215.2 Thousand USD | -2.75% |
| 2020 Q4 | 242.99 Thousand USD | 11.72% |
| 2020 Q2 | 216.33 Thousand USD | 0.52% |
| 2020 Q3 | 217.49 Thousand USD | 0.54% |
| 2020 FY | 242.99 Thousand USD | 9.8% |
| 2019 Q1 | 238.05 Thousand USD | -1.27% |
| 2019 Q2 | 238.45 Thousand USD | 0.17% |
| 2019 Q4 | 221.29 Thousand USD | 0.49% |
| 2019 FY | 221.29 Thousand USD | -8.22% |
| 2019 Q3 | 220.22 Thousand USD | -7.65% |
| 2018 Q1 | 242.8 Thousand USD | -7.09% |
| 2018 Q4 | 241.1 Thousand USD | -8.46% |
| 2018 Q3 | 263.39 Thousand USD | 9.01% |
| 2018 Q2 | 241.62 Thousand USD | -0.49% |
| 2018 FY | 241.1 Thousand USD | -7.74% |
| 2017 Q3 | 228.4 Thousand USD | -2.14% |
| 2017 FY | 261.32 Thousand USD | -11.08% |
| 2017 Q4 | 261.32 Thousand USD | 14.41% |
| 2017 Q2 | 233.39 Thousand USD | -7.5% |
| 2017 Q1 | 252.3 Thousand USD | -14.15% |
| 2016 Q4 | 293.88 Thousand USD | 2.43% |
| 2016 Q1 | 291.46 Thousand USD | 28.16% |
| 2016 Q2 | 266.08 Thousand USD | -8.71% |
| 2016 Q3 | 286.92 Thousand USD | 7.83% |
| 2016 FY | 293.88 Thousand USD | 29.23% |
| 2015 FY | 227.41 Thousand USD | -9.43% |
| 2015 Q4 | 227.41 Thousand USD | -2.76% |
| 2015 Q3 | 233.86 Thousand USD | 21.18% |
| 2015 Q2 | 192.99 Thousand USD | -45.91% |
| 2015 Q1 | 356.77 Thousand USD | 42.09% |
| 2014 Q4 | 251.09 Thousand USD | 14.25% |
| 2014 FY | 251.09 Thousand USD | 234.95% |
| 2014 Q1 | 186.04 Thousand USD | 148.18% |
| 2014 Q3 | 219.77 Thousand USD | -5.97% |
| 2014 Q2 | 233.72 Thousand USD | 25.63% |
| 2013 Q1 | 251.2 Thousand USD | -39.24% |
| 2013 Q4 | 74.96 Thousand USD | -71.54% |
| 2013 FY | 74.96 Thousand USD | -81.87% |
| 2013 Q3 | 263.36 Thousand USD | 10.75% |
| 2013 Q2 | 237.8 Thousand USD | -5.33% |
| 2012 Q2 | 408.18 Thousand USD | 11.52% |
| 2012 Q4 | 413.46 Thousand USD | 3.2% |
| 2012 FY | 413.46 Thousand USD | -9.51% |
| 2012 Q3 | 400.62 Thousand USD | -1.85% |
| 2012 Q1 | 366.03 Thousand USD | -19.89% |
| 2011 Q1 | 456.92 Thousand USD | 0.0% |
| 2011 Q2 | 456.92 Thousand USD | 0.0% |
| 2011 Q3 | 456.92 Thousand USD | 0.0% |
| 2011 Q4 | 456.92 Thousand USD | 0.0% |
| 2011 FY | 456.92 Thousand USD | 0.0% |
| 2010 Q3 | 456.92 Thousand USD | 0.0% |
| 2010 FY | 456.92 Thousand USD | 0.0% |
| 2010 Q2 | 456.92 Thousand USD | 0.0% |
| 2010 Q4 | 456.92 Thousand USD | 0.0% |
| 2010 Q1 | 456.92 Thousand USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 FY | 456.92 Thousand USD | 0.0% |
| 2009 Q4 | 456.92 Thousand USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2006 Q4 | - USD | -100.0% |
| 2006 Q2 | 5 Million USD | 75.44% |
| 2006 Q3 | 2 Million USD | -60.0% |
| 2006 Q1 | 2.85 Million USD | 235.29% |
| 2006 FY | - USD | -100.0% |
| 2005 Q4 | 850 Thousand USD | 0.0% |
| 2005 Q1 | - USD | -100.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 FY | 850 Thousand USD | 69287.76% |
| 2005 Q3 | - USD | 0.0% |
| 2004 FY | 1225.00 USD | 0.0% |
| 2004 Q2 | 10.4 Thousand USD | 108.0% |
| 2004 Q3 | 4368.00 USD | -58.0% |
| 2004 Q4 | 1225.00 USD | -71.96% |
| 2004 Q1 | 5000.00 USD | 0.0% |
| 2003 Q2 | 195.72 Thousand USD | 0.0% |
| 2003 Q1 | 195.72 Thousand USD | 0.0% |
| 2003 FY | - USD | -100.0% |
| 2003 Q3 | 195.72 Thousand USD | 0.0% |
| 2003 Q4 | - USD | -100.0% |
| 2002 Q2 | 195.15 Thousand USD | 0.13% |
| 2002 Q1 | 194.9 Thousand USD | 1.32% |
| 2002 Q3 | 195.72 Thousand USD | 0.29% |
| 2002 Q4 | 195.72 Thousand USD | 0.0% |
| 2002 FY | 195.72 Thousand USD | 1.75% |
| 2001 FY | 192.35 Thousand USD | 0.0% |
| 2001 Q2 | 234.1 Thousand USD | -14.27% |
| 2001 Q3 | 234.1 Thousand USD | 0.0% |
| 2001 Q4 | 192.35 Thousand USD | -17.83% |
| 2001 Q1 | 273.08 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 94.661% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 46.63% |
| SQZ Biotechnologies Company | 27.47 Million USD | 91.992% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 94.928% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 92.61% |
| Mesoblast Limited | 118.7 Million USD | 98.147% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -131.989% |
| Genus plc | 233.1 Million USD | 99.056% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 24.929% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -63.732% |
| Marizyme, Inc. | 18.71 Million USD | 88.247% |
| ContraFect Corporation | 2.88 Million USD | 23.642% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -193.317% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -1523.683% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -52.102% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 5.42% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 61.122% |
| MultiCell Technologies, Inc. | 202.58 USD | -1085831.484% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 96.173% |
| EV Biologics, Inc. | 1.49 Million USD | -47.174% |
| Q BioMed Inc. | 4.1 Million USD | 46.475% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 93.354% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -249.145% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -79.091% |
| Biomind Labs Inc. | 735.54 Thousand USD | -199.083% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 98.718% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 83.074% |
| Skye Bioscience, Inc. | 4.61 Million USD | 52.335% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -147.716% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -1454.488% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 62.53% |
| IMV Inc. | 28.88 Million USD | 92.384% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -8453.521% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 2.59% |
| GB Sciences, Inc. | 1.75 Million USD | -25.042% |
| Alpha Cognition Inc. | 1.22 Million USD | -80.263% |
| HST Global, Inc. | 98.31 Thousand USD | -2137.492% |
| CSL Limited | 12.18 Billion USD | 99.982% |
| Halberd Corporation | 150 Thousand USD | -1366.587% |
| Enzolytics Inc. | 996.33 Thousand USD | -120.797% |
| Resverlogix Corp. | 6.49 Million USD | 66.109% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -360.708% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -760.7% |
| argenx SE | 20 Million USD | 89.001% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 95.171% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 18.785% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -21414.719% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.473% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -996.563% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 8.251% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -859.427% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 96.748% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 27.305% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -511.57% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 89.178% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -1379.866% |
| BioStem Technologies, Inc. | 4.71 Million USD | 53.307% |
| ONE Bio Corp. | 19.71 Million USD | 88.842% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -779.312% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -784.481% |
| Agentix Corp. | 50 Thousand USD | -4299.76% |
| LadRx Corporation | 33.6 Thousand USD | -6446.093% |
| Cell Source, Inc. | 9.25 Million USD | 76.228% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -190.911% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -190.911% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 68.897% |
| Itoco Inc. | 228.37 Thousand USD | -863.267% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -942.721% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 55.852% |
| Kadimastem Ltd | 891.22 Thousand USD | -146.838% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -447.439% |
| CytoDyn Inc. | 30.07 Million USD | 92.686% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -354.254% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -525.238% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 71.868% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -1695.82% |
| Rebus Holdings, Inc. | 310 Thousand USD | -609.639% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 53.543% |
| International Stem Cell Corporation | 4.17 Million USD | 47.346% |
| Bioxytran, Inc. | 1.92 Million USD | -14.279% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -3424.714% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -0.87% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 73.546% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 74.375% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -41.428% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -720.851% |
| Neutra Corp. | 54.15 Thousand USD | -3962.117% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -20.212% |
| PureTech Health plc | 25.51 Million USD | 91.377% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -79.696% |
| IXICO plc | 472.02 Thousand USD | -366.054% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 85.808% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 96.467% |
| CSL Limited | 12.18 Billion USD | 99.982% |
| Cellectis S.A. | 92.77 Million USD | 97.629% |